Literature DB >> 8550565

Ras interaction with two distinct binding domains in Raf-1 may be required for Ras transformation.

J K Drugan1, R Khosravi-Far, M A White, C J Der, Y J Sung, Y W Hwang, S L Campbell.   

Abstract

Although Raf-1 is a critical Ras effector target, how Ras mediates Raf-1 activation remains unresolved. Raf-1 residues 55-131 define a Ras-binding domain essential for Raf-1 activation. Therefore, our identification of a second Ras-binding site in the Raf-1 cysteine-rich domain (residues 139-184) was unexpected and suggested a more complex role for Ras in Raf-1 activation. Both Ras recognition domains preferentially associate with Ras-GTP. Therefore, mutations that impair Ras activity by perturbing regions that distinguish Ras-GDP from Ras-GTP (switch I and II) may disrupt interactions with either Raf-1-binding domain. We observed that mutations of Ras that impaired Ras transformation by perturbing its switch I (T35A and E37G) or switch II (G60A and Y64W) domain preferentially diminished binding to Raf-1-(55-131) or the Raf-1 cysteine-rich domain, respectively. Thus, these Ras-binding domains recognize distinct Ras-GTP determinants, and both may be essential for Ras transforming activity. Finally, since Ha-Ras T35A and E37G mutations prevent Ras interaction with full-length Raf-1, we suggest that Raf-Cys is a cryptic binding site that is unmasked upon Ras interaction with Raf-1-(55-131).

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8550565     DOI: 10.1074/jbc.271.1.233

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  42 in total

1.  The strength of interaction at the Raf cysteine-rich domain is a critical determinant of response of Raf to Ras family small GTPases.

Authors:  T Okada; C D Hu; T G Jin; K Kariya; Y Yamawaki-Kataoka; T Kataoka
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

2.  Phospholipase C(epsilon): a novel Ras effector.

Authors:  G G Kelley; S E Reks; J M Ondrako; A V Smrcka
Journal:  EMBO J       Date:  2001-02-15       Impact factor: 11.598

3.  Critical but distinct roles for the pleckstrin homology and cysteine-rich domains as positive modulators of Vav2 signaling and transformation.

Authors:  Michelle A Booden; Sharon L Campbell; Channing J Der
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

4.  Structural determinants of Ras-Raf interaction analyzed in live cells.

Authors:  Tzvetanka Bondeva; András Balla; Péter Várnai; Tamas Balla
Journal:  Mol Biol Cell       Date:  2002-07       Impact factor: 4.138

Review 5.  New aspects of the molecular constituents of tissue barriers.

Authors:  H C Bauer; A Traweger; J Zweimueller-Mayer; C Lehner; H Tempfer; I Krizbai; I Wilhelm; H Bauer
Journal:  J Neural Transm (Vienna)       Date:  2010-09-24       Impact factor: 3.575

6.  Association of yeast adenylyl cyclase with cyclase-associated protein CAP forms a second Ras-binding site which mediates its Ras-dependent activation.

Authors:  F Shima; T Okada; M Kido; H Sen; Y Tanaka; M Tamada; C D Hu; Y Yamawaki-Kataoka; K Kariya; T Kataoka
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

Review 7.  Inhibition of Ras for cancer treatment: the search continues.

Authors:  Antonio T Baines; Dapeng Xu; Channing J Der
Journal:  Future Med Chem       Date:  2011-10       Impact factor: 3.808

Review 8.  Ras plasma membrane signalling platforms.

Authors:  John F Hancock; Robert G Parton
Journal:  Biochem J       Date:  2005-07-01       Impact factor: 3.857

9.  Ras binding opens c-Raf to expose the docking site for mitogen-activated protein kinase kinase.

Authors:  Kenta Terai; Michiyuki Matsuda
Journal:  EMBO Rep       Date:  2005-03       Impact factor: 8.807

Review 10.  The Mystery of Rap1 Suppression of Oncogenic Ras.

Authors:  Ruth Nussinov; Hyunbum Jang; Mingzhen Zhang; Chung-Jung Tsai; Anna A Sablina
Journal:  Trends Cancer       Date:  2020-03-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.